Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check26 days agoChange DetectedThe page has been updated to include new drug information related to breast cancer treatments, specifically mentioning Doxorubicin, Epirubicin, Cyclophosphamide, and endocrine therapy, while significant details about the study involving pembrolizumab have been removed.SummaryDifference15%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check48 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check100 days agoChange DetectedThe website has updated to revision v2.14.2, noting that some NLM-NCBI services are experiencing heavy traffic, which may impact performance and availability.SummaryDifference0.5%
Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.